We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

76 hedge funds and large institutions have $302M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

13% more funds holding

Funds holding: 67 → 76 (+9)

28% less capital invested

Capital invested by funds: $421M → $302M (-$119M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
76
Holders Change
+9
Holders Change %
+13.43%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
23
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$16.6M
2
HighTower Advisors
HighTower Advisors
Illinois
+$15.2M
3
BlackRock
BlackRock
New York
+$7.5M
4
Morgan Stanley
Morgan Stanley
New York
+$3.66M
5
Bank of America
Bank of America
North Carolina
+$3.05M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$15.3M
2
RCM
RA Capital Management
Massachusetts
-$7.77M
3
EC
EcoR1 Capital
California
-$5.47M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.35M
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$914K
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
51
New York State Common Retirement Fund
New York
$160K – – –
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$145K -$10.8K -808 -5%
Jane Street
53
Jane Street
New York
$125K +$165K +12,286 New
MIH
54
Meitav Investment House
Israel
$122K +$161K +12,000 New
Wells Fargo
55
Wells Fargo
California
$97K -$21.8K -1,628 -15%
TRCT
56
Tower Research Capital (TRC)
New York
$96K +$70.3K +5,241 +124%
AIG
57
American International Group
New York
$87K -$2.6K -194 -2%
Deutsche Bank
58
Deutsche Bank
Germany
$80K +$9.23K +688 +10%
ED
59
Exane Derivatives
France
$37.7K +$49.6K +3,700 New
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$34.2K +$37.4K +2,789 +491%
Citigroup
61
Citigroup
New York
$27K -$17.6K -1,314 -33%
Legal & General Group
62
Legal & General Group
United Kingdom
$18K -$6.53K -487 -21%
AIP
63
Ameritas Investment Partners
Nebraska
$12K – – –
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$9K -$282 -21 -2%
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
$7K -$6.4K -477 -42%
US Bancorp
66
US Bancorp
Minnesota
$6K – – –
ASN
67
Advisory Services Network
Georgia
$4K +$5.37K +400 New
CSS
68
Cubist Systematic Strategies
Connecticut
$3K +$4.03K +300 New
Daiwa Securities Group
69
Daiwa Securities Group
Japan
$2K – – –
TPWA
70
TRUE Private Wealth Advisors
Oregon
$2K – – –
PCM
71
Penserra Capital Management
California
$2K +$3.92K +292 New
IRC
72
Investors Research Corp
Georgia
$1K +$832 +62 New
Group One Trading
73
Group One Trading
Illinois
$1K +$1.34K +100 New
SBL
74
Sargent Bickham Lagudis
Colorado
$1K +$1.34K +100 New
Millennium Management
75
Millennium Management
New York
$672 -$829K -61,789 -48%
1 2
3
4

PRVL Hedge Fund Activity: Q3 2020 in Review

76 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q3 2020, worth a combined $302M — down 28% from $421M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PRVL positions and 11 closed out — a net gain of 9 holders — while 23 added to existing stakes and 18 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.3M sold.

  • 76 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q3 2020, up from 67 in Q2 2020.
  • Funds reported $302M of Prevail Therapeutics Inc. Common Stock stock for Q3 2020, down 28% quarter-over-quarter.
  • 20 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q3 2020 and 11 closed out, a net change of +9 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q3 2020 was Citadel Advisors, an estimated $16.6M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q3 2020 was Avidity Partners Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2020.